
Neurodegenerative diseases such as Alzheimer’s disease and dementia with Lewy body (DLB) are caused by the accumulation of aggregated amyloid beta and ?-synucelin, respectively. The aggregated proteins impaired the proteasome activity, thereby exacerbating neuronal death. On the other hand, we developed a novel T-type calcium channel enhancer SAK3 in 2017. Since T-type calcium channel is critical for neurotransmitter release, SAK3 enhanced the acetylcholine release in the brain thereby improving learning and memory. We here found that calcium entry through T-type calcium channel activates protein kinase (CaMKII), thereby promoting Rpt-6 phosphorylation. The Rpt-6 phosphorylation promoted the degradation of aggregated amyloid beta and ?-synucelin in neurons. This is the first disease modifying therapeutics in most neurodegenerative diseases such as Alzheimer’s disease, dementia with Lewy body (DLB), Huntington disease (HD) and frontotemporal dementia (FTD). Credit: Kohji Fukunaga
Researchers have identified a new treatment candidate that appears to not only halt neurodegenerative symptoms in mouse models of dementia and Alzheimer’s disease, but also reverse the effects of the disorders.
The team, based at Tohoku University, published their results on June 8 in the International Journal of Molecular Sciences. The treatment candidate has been declared safe by Japan’s governing board, and the researchers plan to begin clinical trials in humans in the next year.
“There are currently no disease-modifying therapeutics for neurodegenerative disorders such as Alzheimer’s disease, Lewy body dementia, Huntington disease and frontotemporal dementia in the world,” said paper author Kohji Fukunaga, professor emeritus in Tohoku University’s Graduate School of Pharmaceutical Sciences. “We discovered the novel, disease-modifying therapeutic candidate SAK3, which, in our studies, rescued neurons in most protein-misfolding, neurodegenerative diseases.”
In a previous study, the team found that the SAK3 molecule – the base structure of which is found in the enhancement of T-type Ca2+ channel activity – appeared to help improve memory and learning in a mouse model of Alzheimer’s disease.
According to previous studies, SAK3 enhances the function of a cell membrane channel thereby promoting neuronal activity in the brain. Typically, SAK3 promotes neurotransmitter releases of acetylcholine and dopamine that are significantly reduced in Alzheimer’s disease and Lewy body dementia. The Ca2+ channel enhancement is thought to trigger a change from resting to active in neuronal activity. When the Ca2+ channel is dysregulated in the brain, the acetylcholine and dopamine releases are reduced. The result is a dysregulated system that a person experiences as cognitive confusion and uncoordinated motor function.
SAK3 directly binds to the subunit of this channel, resulting in the enhancement of neurotransmission thereby improving cognitive deficits. The researchers found that the same process also appeared to work in a mouse model of Lewy body dementia, which is characterized by a build-up of proteins known as Lewy bodies.
“Even after the onset of cognitive impairment, SAK3 administration significantly prevented the progression of neurodegenerative behaviors in both motor dysfunction and cognition,” Fukunaga said.
In comparison, Aduhelm, the Alzheimer’s drug recently approved by the U.S. Food and Drug Administration, reduces the number of amyloid plaques in the brain, but it is not yet known if the amyloid reduction actually prevents further cognitive or motor decline in patients. According to Fukunaga, SAK3 helps destroy amyloid plaque – at least in mice.
SAK3 also helps manage the destruction of misfolded alpha-synuclein. Normal alpha-synuclein helps regulate neurotransmitter transmission in the brain. The protein can misfold and aggregate, contributing to what researchers suspect may be an underlying cause of neurodegenerative symptoms. This aggregation can also lead to the loss of dopamine neurons, which help with learning and memory.
“We found that chronic administration of SAK3 significantly inhibited the accumulation of alpha-synuclein in the mice,” Fukunaga said, noting that the mice received a daily oral dose of SAK3.
According to Fukunaga, SAK3 enhances the activity of the system that identifies and destroys misfolded proteins. In neurodegenerative diseases, this system is often dysfunctional, leaving misfolded proteins to muck up the cell’s machinery.
“SAK3 is the first compound targeting this regulatory activity in neurodegenerative disorders,” Fukunaga said. “SAK3 administration promotes the destruction of misfolded proteins, meaning the therapeutic has the potential to solve the problems of diverse protein misfolding diseases such as Parkinson’s disease, Lewy body dementia and Huntington disease, in addition to Alzheimer’s disease.”
Original Article: Success in Reversing Dementia in Mice Sets the Stage for Human Clinical Trials
More from: Tohoku University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Reversing Alzheimer’s
- Dr. Stephen Manlove, From Manlove Brain and Body Health, Is Hosting a Free Educational Session–Preventing and Reversing Alzheimer’s Disease
This helps the brain function at its best to decrease the likelihood of developing Alzheimer’s Disease or even reverse its course,” says Dr. Manlove. Event: Preventing and Reversing Alzheimer ...
- SMART LIVING: Reverse cognitive decline
Forgetting is a classic sign of cognitive decline. However, not all memory issues are irreversible. An instant way to begin saving yourself is to quit smoking. A study out of Ohio State University ...
- Dr. Stephen Manlove, From Manlove Brain and Body Health, Is Hosting a Free Educational Session–Preventing and Reversing Alzheimer's Disease
This helps the brain function at its best to decrease the likelihood of developing Alzheimer's Disease or even reverse its course," says Dr. Manlove.
- Dr. Stephen Manlove, From Manlove Brain and Body Health, Is Hosting a Free Educational Session–Preventing and Reversing Alzheimer’s Disease
Psychiatrist Dr. Stephen Manlove will host a free educational talk–Preventing and Reversing Alzheimer’s Disease–at the Rapid City Library on 3/27.
- Number of Alzheimer patients expected to double by 2050
A study by the Alzheimer’s Association expects the number of Alzheimer patients to double by the year 2050. “We’ve seen the numbers go up in southern Colorado and throughout the entire country.” said ...
Go deeper with Google Headlines on:
Reversing Alzheimer’s
[google_news title=”” keyword=”reversing Alzheimer’s” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Reversing dementia
- The Added Burden of Dementia for Women
Women make up a significant majority of those living with dementia today. In the U.S., for example, roughly two-thirds of the estimated 6 million-plus people living with dementia are women. While the ...
- The toll of dementia
André Picard, in his 2021 book on senior care, says “contrary to common perceptions, more than half of people with dementia stay at home.” A 2022 report by Alzheimer Society of Canada placed ...
- Unlocking the Potential of CRISPR for Reversing Vision Loss
Is there a connection between Osteoporosis and dementia? Yes, loss in bone density may be linked to an increased risk of dementia in older age. Link between chromosome length and biological aging ...
- Dementia risk higher for elite soccer players, study finds
Alzheimer's disease and dementia were 62% more common among soccer players. This is a MedPage Today story. Men who played elite soccer were more likely to develop neurodegenerative diseases ...
- askST: Can frailty among the elderly be reversed?
Doctors believe that frailty among the elderly leads to falls, longer hospital stays and poor recovery. Read more at straitstimes.com.
Go deeper with Google Headlines on:
Reversing dementia
[google_news title=”” keyword=”reversing dementia” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]